The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform. Novo Nordisk gets a license to three preclinical-stage cardiovascular disease programmes from Valo Health...

  Sandoz, a global leader in generic and biosimilar medicines, announced that it has entered into a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the...

  Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The European approval for Tyruko comes a month...

  Italian company Alfasigma has signed a definitive agreement for the acquisition of all issued and outstanding shares in Intercept Pharmaceuticals. Alfasigma will pay $19 for each share of Intercept. The acquisition will help boost Alfasigma’s gastroenterology and hepatology...